355 related articles for article (PubMed ID: 25056838)
1. The health economics of bladder cancer: an updated review of the published literature.
Yeung C; Dinh T; Lee J
Pharmacoeconomics; 2014 Nov; 32(11):1093-104. PubMed ID: 25056838
[TBL] [Abstract][Full Text] [Related]
2. The health economics of bladder cancer: a comprehensive review of the published literature.
Botteman MF; Pashos CL; Redaelli A; Laskin B; Hauser R
Pharmacoeconomics; 2003; 21(18):1315-30. PubMed ID: 14750899
[TBL] [Abstract][Full Text] [Related]
3. The economics of bladder cancer: costs and considerations of caring for this disease.
Svatek RS; Hollenbeck BK; Holmäng S; Lee R; Kim SP; Stenzl A; Lotan Y
Eur Urol; 2014 Aug; 66(2):253-62. PubMed ID: 24472711
[TBL] [Abstract][Full Text] [Related]
4. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness.
Tandogdu Z; Lewis R; Duncan A; Penegar S; McDonald A; Vale L; Shen J; Kelly JD; Pickard R; N Dow J; Ramsay C; Mostafid H; Mariappan P; Nabi G; Creswell J; Lazarowicz H; McGrath J; Taylor E; Clark E; Maclennan G; Norrie J; Hall E; Heer R;
BMJ Open; 2019 Sep; 9(9):e022268. PubMed ID: 31481549
[TBL] [Abstract][Full Text] [Related]
6. Cost-effective treatment of low-risk carcinoma not invading bladder muscle.
Green DA; Rink M; Cha EK; Xylinas E; Chughtai B; Scherr DS; Shariat SF; Lee RK
BJU Int; 2013 Mar; 111(3 Pt B):E78-84. PubMed ID: 22958598
[TBL] [Abstract][Full Text] [Related]
7. Cost comparison between open radical cystectomy, laparoscopic radical cystectomy, and robot-assisted radical cystectomy for patients with bladder cancer: a systematic review of segmental costs.
Morii Y; Osawa T; Suzuki T; Shinohara N; Harabayashi T; Ishikawa T; Tanikawa T; Yamashina H; Ogasawara K
BMC Urol; 2019 Nov; 19(1):110. PubMed ID: 31703573
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort.
Kukreja JB; Metcalfe MJ; Qiao W; Kamat AM; Dinney CPN; Navai N
Eur Urol Focus; 2020 Jan; 6(1):88-94. PubMed ID: 30033071
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer.
Kulkarni GS; Alibhai SM; Finelli A; Fleshner NE; Jewett MA; Lopushinsky SR; Bayoumi AM
Cancer; 2009 Dec; 115(23):5450-9. PubMed ID: 19685529
[TBL] [Abstract][Full Text] [Related]
10. Economic Burden of Bladder Cancer Across the European Union.
Leal J; Luengo-Fernandez R; Sullivan R; Witjes JA
Eur Urol; 2016 Mar; 69(3):438-47. PubMed ID: 26508308
[TBL] [Abstract][Full Text] [Related]
11. Economic aspects of bladder cancer: what are the benefits and costs?
Sievert KD; Amend B; Nagele U; Schilling D; Bedke J; Horstmann M; Hennenlotter J; Kruck S; Stenzl A
World J Urol; 2009 Jun; 27(3):295-300. PubMed ID: 19271220
[TBL] [Abstract][Full Text] [Related]
12. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review.
Perlis N; Zlotta AR; Beyene J; Finelli A; Fleshner NE; Kulkarni GS
Eur Urol; 2013 Sep; 64(3):421-30. PubMed ID: 23830475
[TBL] [Abstract][Full Text] [Related]
13. Healthcare economics of bladder cancer: cost-enhancing and cost-reducing factors.
Noyes K; Singer EA; Messing EM
Curr Opin Urol; 2008 Sep; 18(5):533-9. PubMed ID: 18670280
[TBL] [Abstract][Full Text] [Related]
14. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
[TBL] [Abstract][Full Text] [Related]
15. [Cost-effectiveness of transurethral resection of the bladder with blue light in patients with non muscle invasive bladder cancer in France].
Rouprêt M; Malavaud B; Molinier L; Leleu H; Blachier M; Marteau F
Prog Urol; 2015 Apr; 25(5):256-64. PubMed ID: 25605343
[TBL] [Abstract][Full Text] [Related]
16. Intravesical therapy for bladder cancer.
Williams SK; Hoenig DM; Ghavamian R; Soloway M
Expert Opin Pharmacother; 2010 Apr; 11(6):947-58. PubMed ID: 20205607
[TBL] [Abstract][Full Text] [Related]
17. Surgical advances in bladder cancer: at what cost?
Johnson DC; Greene PS; Nielsen ME
Urol Clin North Am; 2015 May; 42(2):235-52, ix. PubMed ID: 25882565
[TBL] [Abstract][Full Text] [Related]
18. Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin.
Marchetti A; Wang L; Magar R; Grossman HB; Lamm DL; Schellhammer PF; Erwin-Toth P
Clin Ther; 2000 Apr; 22(4):422-38. PubMed ID: 10823364
[TBL] [Abstract][Full Text] [Related]
19. Updates on intravesical therapy.
Pisano F; Vila Reyes H; Breda A; Palou J
Curr Opin Urol; 2019 Nov; 29(6):649-655. PubMed ID: 31567439
[TBL] [Abstract][Full Text] [Related]
20. Cost analysis of open radical cystectomy versus robot-assisted radical cystectomy.
Mmeje CO; Martin AD; Nunez-Nateras R; Parker AS; Thiel DD; Castle EP
Curr Urol Rep; 2013 Feb; 14(1):26-31. PubMed ID: 23184624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
